Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) saw unusually large options trading activity on Monday. Stock traders bought 5,081 call options on the stock. This represents an increase of approximately 428% compared to the average daily volume of 962 call options.
Checkpoint Therapeutics Stock Performance
Shares of NASDAQ:CKPT traded up $1.56 during trading on Monday, reaching $4.03. 31,418,626 shares of the stock were exchanged, compared to its average volume of 1,431,565. Checkpoint Therapeutics has a 12-month low of $1.38 and a 12-month high of $4.50. The firm's 50-day moving average price is $3.10 and its 200 day moving average price is $3.08. The firm has a market cap of $196.55 million, a price-to-earnings ratio of -2.19 and a beta of 1.41.
Analyst Upgrades and Downgrades
Several research firms have commented on CKPT. Lake Street Capital lifted their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a "buy" rating in a report on Monday, December 16th. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a report on Monday, December 16th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $4.80 price target (down previously from $9.00) on shares of Checkpoint Therapeutics in a research report on Monday.
Read Our Latest Stock Report on CKPT
Insider Transactions at Checkpoint Therapeutics
In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 268,432 shares of Checkpoint Therapeutics stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the completion of the transaction, the chief financial officer now owns 1,032,754 shares in the company, valued at approximately $4,141,343.54. The trade was a 20.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO James F. Oliviero III sold 10,331 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $3.15, for a total value of $32,542.65. Following the sale, the chief executive officer now owns 3,775,019 shares in the company, valued at approximately $11,891,309.85. This trade represents a 0.27 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 582,336 shares of company stock worth $2,156,801. Company insiders own 2.10% of the company's stock.
Hedge Funds Weigh In On Checkpoint Therapeutics
Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its holdings in Checkpoint Therapeutics by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 445,111 shares of the company's stock valued at $1,425,000 after purchasing an additional 17,460 shares in the last quarter. 683 Capital Management LLC acquired a new stake in shares of Checkpoint Therapeutics in the fourth quarter valued at about $522,000. HB Wealth Management LLC raised its holdings in shares of Checkpoint Therapeutics by 96.9% during the 4th quarter. HB Wealth Management LLC now owns 153,560 shares of the company's stock valued at $513,000 after buying an additional 75,560 shares during the period. PVG Asset Management Corp lifted its position in Checkpoint Therapeutics by 9.2% during the 3rd quarter. PVG Asset Management Corp now owns 149,870 shares of the company's stock worth $336,000 after acquiring an additional 12,676 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Checkpoint Therapeutics by 160.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company's stock worth $291,000 after acquiring an additional 80,000 shares during the period. Hedge funds and other institutional investors own 22.00% of the company's stock.
About Checkpoint Therapeutics
(
Get Free Report)
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Checkpoint Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Checkpoint Therapeutics wasn't on the list.
While Checkpoint Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
